This randomized clinical trial assesses whether neoadjuvant fulvestrant or anastrozole plus fulvestrant vs anastrozole alone increases endocrine-sensitive disease rate (ESDR) in postmenopausal women with estrogen receptor (ER)–rich/ERBB2-negative breast cancer. Here, ESR1 is linked to breast carcinoma.